Connection

Jinghua Yan to Adult

Back to Details
This is a "connection" page, showing publications Jinghua Yan has written about Adult.
Jinghua Yan
Connection Strength
0.017
Adult
  1. Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study. Antimicrob Agents Chemother. 2021 07 16; 65(8):e0035021.
    View in: PubMed
    Score: 0.004
  2. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021 08; 21(8):1107-1119.
    View in: PubMed
    Score: 0.004
  3. Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab. Cell Rep. 2018 10 23; 25(4):909-920.e4.
    View in: PubMed
    Score: 0.003
  4. Hemagglutinin-specific CD4+ T-cell responses following 2009-pH1N1 inactivated split-vaccine inoculation in humans. Vaccine. 2017 10 09; 35(42):5644-5652.
    View in: PubMed
    Score: 0.003
  5. CTL immunogenicity of Rv3615c antigen and diagnostic performances of an ESAT-6/CFP-10/Rv3615c antigen cocktail for Mycobacterium tuberculosis infection. Tuberculosis (Edinb). 2017 12; 107:5-12.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.